Publicaciones en colaboración con investigadores/as de Tel Aviv Sourasky Medical Center (13)

2024

  1. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study

    Nature Medicine, Vol. 30, Núm. 7, pp. 2020-2029

2023

  1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  2. Long-term safety of spinal cord stimulation systems in a prospective, global registry of patients with chronic pain

    Pain Management, Vol. 13, Núm. 2, pp. 115-127

  3. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

    Leukemia Research, Vol. 134

2021

  1. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027

2020

  1. Predictors for anastomotic leak, postoperative complications, and mortality after right colectomy for cancer: Results from an international snapshot audit

    Diseases of the Colon and Rectum

2019

  1. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

    The Lancet Haematology, Vol. 6, Núm. 9, pp. e448-e458

  2. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469

2018

  1. Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO

    Colorectal Disease, Vol. 20, Núm. 3, pp. 219-227

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

    Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052

2015

  1. Role of Systemic Anti-Tumor Necrosis Factor Alpha Treatment in the Reduction of Proliferative Vitreoretinopathy

    Journal of Clinical & Experimental Ophthalmology, Vol. 06, Núm. 04

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051